Cytiva supports Clover Biopharmaceuticals to scale up the output of its vaccine candidate

Clover aims to double its commercial manufacturing capacity in preparation for global Phase 2/3 trials Cytiva provides FlexFactory™ bioprocessing upstream and downstream solutions for Clover to accelerate GMP facility development and shorten time to market SHANGHAI, Nov. 16, 2020...

from PR Newswire: https://ift.tt/35BeRKu